{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-075722","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2024-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.727104+00:00","generated_at":"2026-06-01T01:04:07.910503+00:00","sec_items":["1.02","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Alvogen terminates NRX-101 pact; NRx eyes accelerated FDA filing","bullets":["Alvogen terminated exclusive development and license agreement for NRX-101 effective June 21, 2024.","Alvogen claims $4,502,705 in advanced amounts; parties to negotiate royalty within 30 days.","NRx plans Accelerated Approval filing this year for suicidal bipolar depression, citing trial data.","Company continues NDA submission for intravenous ketamine (NRX-100) in 2024.","NRx estimates $3.7B addressable market for NRX-101 in high-risk patients without viable alternatives."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-075722","json":"https://secwatch.observer/filing/0001104659-24-075722.json","markdown":"https://secwatch.observer/filing/0001104659-24-075722.md","text":"https://secwatch.observer/filing/0001104659-24-075722.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000110465924075722/0001104659-24-075722-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000110465924075722/tm2418373d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T01:04:07.910503+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}